In:
Oncology, S. Karger AG, Vol. 93, No. 3 ( 2017), p. 177-182
Kurzfassung:
〈 b 〉 〈 i 〉 Objective: 〈 /i 〉 〈 /b 〉 The aim of this study was to investigate the clinical usefulness of amrubicin therapy for patients with non-gastrointestinal (GI) non-pancreatic extrapulmonary neuroendocrine carcinoma (EP-NEC). 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 The medical records of patients from the 2 participating institutions were retrospectively reviewed. The eligibility criteria were: patients with non-GI non-pancreatic EP-NEC who received amrubicin monotherapy after platinum-based chemotherapy. Patients in whom the platinum-free interval (interval between the last day of platinum administration and the first subsequent documentation of disease progression) was 90 days or longer were classified into the platinum-sensitive group. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 The study was conducted in a total of 13 patients identified as eligible. The response rate was 45.4% (5/11). The median progression-free survival and overall survival were 6.0 and 10.6 months, respectively. A platinum-free interval of ≥90 days was identified as a significant predictor of a longer progression-free survival time. Grade 3 or 4 neutropenia was observed in 61.5% (8/13) of the patients. One patient died of treatment-related febrile neutropenia. 〈 b 〉 〈 i 〉 Conclusions: 〈 /i 〉 〈 /b 〉 Amrubicin monotherapy as second-line chemotherapy after failure of first-line platinum-based chemotherapy showed good efficacy in patients with non-GI non-pancreatic EP-NEC. Neutropenia was encountered as the most serious adverse event.
Materialart:
Online-Ressource
ISSN:
0030-2414
,
1423-0232
Sprache:
Englisch
Verlag:
S. Karger AG
Publikationsdatum:
2017
ZDB Id:
1483096-6
ZDB Id:
250101-6
